This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) ##STR00001##

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) ##STR00001##

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.

The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

Provided herein are certain inhibitors of ROCK (rho-kinases or rho-associated kinases), which are useful as medicament, for the treatment Huntington's disease in particular.

##STR00001##